EUCTR2016-000818-29-GB进行中（未招募）1 期
A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrome with Constipation
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participant has provided written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.
- •2. Participant is a male or non-pregnant, non-breastfeeding female, and is age 18 years or older (no upper age limit).
- •3. Female participants of childbearing potential must complete a urine pregnancy test with negative results at the Screening Visit (Visit 1) and again at the Randomisation Visit (Visit 4) prior to dosing.
- •4. Female participants who are pre-menopausal should be enrolled between days 7 and 21 of their menstrual cycle.
- •5. Sexually active female participants of childbearing potential must agree to use one of the following methods of contraception from the date that they sign the ICF until the end of study:
- •a. Hormonal contraception (i.e., oral contraceptive, contraceptive implant, or injectable hormonal contraceptive);
- •b. Intra-uterine device (IUD);
- •c. A barrier birth control (such as condoms or occlusive cap with spermicidal foam/gel/film/cream/suppository);
- •d. Surgical sterilisation (i.e., bilateral oophorectomy, hysterectomy, or tubal ligation);
- •e. Abstinence, when in the opinion of the Investigator, the participant’s occupation or lifestyle gives sufficient evidence that abstinence will be maintained throughout the study and for 1 month thereafter.
- •6. Participant meets Rome III criteria for IBS-C, as well as abdominal pain score (average of = 3 on 0-10 point numerical rating scale [NRS]), abdominal bloating score (average of = 5 on 0-10 point NRS), and abdominal girth measurement (AIP increase of > 4 cm) criteria during the Pretreatment Period.
- •7. Participant agrees to refrain from strenuous physical activity for 24 hours prior to each study visit.
- •8. Participant agrees to refrain from initiating any lifestyle or dietary changes.
- •9. Participant agrees to refrain from taking any probiotics from 14 days prior to enrolment in the study throughout the Treatment Period.
- •10. Participant is able to communicate well with the Investigator and to comply with the requirements for the entire study.
- •11. Participant has a body mass index (BMI) between 18.5 and 34.9 kg/m2 (bounds included) at the Screening Visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Participant reports loose (mushy) or watery stools (BSFS score of 6 or 7) in the absence of any laxative, suppository, enema, or prohibited medicine (as described in Appendix 1) for > 25% of BMs during the 12 weeks before the Screening Visit.
- •2. Participant has ever had a diagnosis of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or any other form of familial colorectal cancer, or inflammatory bowel disease.
- •3. Participant currently has both unexplained and clinically significant alarm symptoms (lower GI bleeding, iron-deficiency anaemia or any unexplained anaemia, or weight loss) or systemic signs of infection or colitis.
- •4. Participant currently has active peptic ulcer disease (i.e., disease that is not adequately treated or stable with therapy).
- •5. Participant has a history of any chronic GI condition (e.g., diverticulitis) that can be associated with abdominal pain or discomfort.
- •6. Participant has CNS disease or any organic condition associated with constipation.
- •7. Participant has had surgery that meets any of the following criteria:
- •a. Has undergone any surgery within 6 months prior to the Screening Visit;
- •b. Has had previous abdominal surgery except appendectomy, cholecystectomy, or hysterectomy.
- •8. Participant has diabetes.
- •9. Participant reports using a Prohibited Medicine (excluding laxatives, suppositories, and enemas) during the Pretreatment Period or is not willing or able to abide by the restrictions regarding use of Prohibited Medicines defined in Appendix 1. (Note: the use of fibre, bulk laxatives, or stool softeners [such as docusate] is acceptable provided that the participant has been on a stable dose during the 30 days before the Screening Visit and plans to continue on
- •a stable dose throughout the study.)
- •10. Participant has taken commercially available linaclotide during the 30 days prior to the Screening Visit.
- •11. Participant is drinking alcohol above the recommended safe alcohol limit (< 21 units/week) or abusing drugs. In addition, participants will be asked to refrain from drinking alcohol for 24 hours before plethysmography recordings until belt removal.
- •12. Participant has lactose intolerance.
- •13. Participant has an acute or chronic condition that, in the Investigator’s opinion, would limit the participant’s ability to complete or participate in this clinical study.
- •14. Participant is involved in this study as an Investigator, sub-Investigator, study coordinator, other study staff, or Sponsor member.
- •15. Participant has a known or suspected mechanical gastrointestinal obstruction.
- •16. Participant has a history of hypersensitivity to linaclotide or to any of the excipients contained in the study drug (active or placebo).
研究者
相似试验
进行中（未招募）
1 期
A Study to assess the safety and efficacy of SPD489 compared with Concerta with a placebo reference arm on patients aged 13-17 years with Attention-Deficit/Hyperactivity DisorderAttention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivityMedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2011-005452-34-ITShire Development LLC542
进行中（未招募）
不适用
A Study to assess the safety and efficacy of SPD489 compared with Concerta with a placebo reference arm on patients aged 13-17 years with Attention-Deficit/Hyperactivity DisorderAttention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivityMedDRA version: 16.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2011-005452-34-DEShire Development LLC542
进行中（未招募）
不适用
A Study to assess the safety and efficacy of SPD489 compared with Concerta with a placebo reference arm on patients aged 13-17 years with Attention-Deficit/Hyperactivity DisorderEUCTR2011-005452-34-SEShire Development LLC542
进行中（未招募）
不适用
A Study to assess the safety and efficacy of SPD489 compared with Concerta with a placebo reference arm on patients aged 13-17 years with Attention-Deficit/Hyperactivity DisorderAttention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivityMedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2011-005452-34-HUShire Development LLC542
已完成
4 期
A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with empagliflozin (SGLT-2 inhibitor) and losartan (RAS inhibitor) in metformin and/or SU-treated patients with type 2 diabetes mellitus10029149adult-onset diabetes1001842410003216Type 2 Diabetes MellitusNL-OMON49031Vrije Universiteit Medisch Centrum24